Wave Life Sciences Ltd. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Wave Life Sciences Ltd. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.68M | Mar 12, 2018 |
| FY2017 | Sep 30, 2017 | $676.0K | Mar 12, 2018 |
| FY2017 | Jun 30, 2017 | $676.0K | Mar 12, 2018 |
| FY2017 | Mar 31, 2017 | $676.0K | Mar 12, 2018 |
| FY2017 | Dec 31, 2016 | $676.0K | Mar 12, 2018 |
| FY2017 | Sep 30, 2016 | $392.0K | Mar 12, 2018 |
| FY2017 | Jun 30, 2016 | $417.0K | Mar 12, 2018 |
| FY2017 | Dec 31, 2015 | $152.0K | Mar 12, 2018 |
| FY2016 | Jun 30, 2015 | $126.0K | Mar 16, 2017 |
| FY2016 | Mar 31, 2015 | $26.0K | Mar 16, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.73M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $108.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $113.31M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $3.65M | Mar 4, 2025 |
| FY2022 | Dec 31, 2021 | $40.96M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $20.08M | Mar 3, 2022 |
| FY2019 | Dec 31, 2019 | $2.40M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $2.93M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $7.63M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $3.03M | Mar 2, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($204.38M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($97.01M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($57.51M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($161.82M) | Mar 4, 2025 |
| FY2022 | Dec 31, 2021 | ($122.25M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($149.91M) | Mar 3, 2022 |
| FY2019 | Dec 31, 2019 | ($56.77M) | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | ($50.73M) | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | ($41.94M) | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | ($44.20M) | Mar 2, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($215.38M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($110.40M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($68.00M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($162.72M) | Mar 4, 2025 |
| FY2022 | Dec 31, 2021 | ($127.02M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($153.38M) | Mar 3, 2022 |
| FY2019 | Dec 31, 2019 | ($60.53M) | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | ($54.18M) | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | ($45.62M) | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | ($47.99M) | Mar 2, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.78M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $159.68M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $130.01M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $115.86M | Mar 4, 2025 |
| FY2022 | Dec 31, 2021 | $121.88M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $130.94M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $175.43M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $134.43M | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | $79.31M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $40.82M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($187.49M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($151.03M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($19.43M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($127.78M) | Mar 4, 2025 |
| FY2022 | Dec 31, 2021 | ($88.99M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($115.98M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($188.23M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($22.86M) | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | ($83.67M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($31.93M) | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $718.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $938.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.12M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.36M | Mar 4, 2025 |
| FY2022 | Dec 31, 2021 | $560.0K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.34M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $3.92M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $9.94M | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | $18.89M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $5.57M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $638.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $352.21M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $274.95M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $146.39M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $207.01M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $279.24M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $284.25M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $295.94M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $181.84M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $164.81M | Mar 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.27M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $134.82M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $227.45M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $183.60M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $166.64M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $188.59M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $212.64M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $214.72M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $34.36M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $22.07M | Mar 12, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $518.36M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $209.52M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $39.63M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | ($45.09M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $32.50M | Mar 4, 2025 |
| FY2022 | Dec 31, 2020 | $82.78M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $63.73M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | $73.35M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $139.61M | Mar 2, 2020 |
| FY2019 | Dec 31, 2016 | $134.60M | Mar 2, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.33B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.12B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($1.02B) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($967.34M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($805.51M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($683.27M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($533.36M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($339.72M) | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | ($192.72M) | Mar 2, 2020 |
| FY2017 | Dec 31, 2016 | ($90.48M) | Mar 12, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $602.07M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $302.08M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $200.35M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $88.50M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $150.56M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $184.50M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $147.16M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $174.82M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $142.50M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $150.29M | Mar 12, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Mar 4, 2025 |
| FY2022 | Dec 31, 2021 | (2) | Mar 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Mar 4, 2025 |
| FY2022 | Dec 31, 2021 | (2) | Mar 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 187.66M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 153.04M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 119.16M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 86.92M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | 59.84M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 48.78M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | 34.34M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | 29.47M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 27.83M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 23.50M | Mar 12, 2018 |